The new indication follows positive results in a phase III trial that found children and adolescents living with type 1 diabetes (T1D) achieved comparable reduction in average blood sugar (HbA1c) and similar risk of low blood sugar events with Toujeo when compared to insulin glargine 100 units/mL (Gla-100)
Tirzepatide + Future agents or triple agonists Tirzepatide monotherapy induces Weight loss up to 22.5%, reducing the need for adjuncts in most patients
Exercise provides benefits that medications alone cannot
adults had already taken GLP-1 at some point and the global market is projected to triple in the next five years, driven by high and rising levels of type-2 diabetes and obesity, aging populations, urbanization and public health initiatives: (2018-2030E) Global pharmaceutical companies dominate todays production: With ~300 clinical trials around the world, research continues into applications to other metabolic disorders, cardiovascular and kidney disease and neurological conditions
PMID: 37969012 Solvent & Solubility In Vitro : DMSO : 100 mg/mL ( 226.90 mM
Unflavored for versatile mixing
